Your browser doesn't support javascript.
loading
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Armenia, D; Di Carlo, D; Calcagno, A; Vendemiati, G; Forbici, F; Bertoli, A; Berno, G; Carta, S; Continenza, F; Fedele, V; Bellagamba, R; Cicalini, S; Ammassari, A; Libertone, R; Zaccarelli, M; Ghisetti, V; Andreoni, M; Ceccherini-Silberstein, F; Bonora, S; Di Perri, G; Antinori, A; Perno, C F; Santoro, M M.
Afiliación
  • Armenia D; Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
  • Di Carlo D; Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
  • Calcagno A; Division of Infectious Diseases, University of Turin, Turin, Italy.
  • Vendemiati G; Division of Infectious Diseases, University of Turin, Turin, Italy.
  • Forbici F; Antiretroviral Drug Monitoring Laboratory, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Bertoli A; Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
  • Berno G; Antiretroviral Drug Monitoring Laboratory, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Carta S; Antiretroviral Drug Monitoring Laboratory, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Continenza F; Antiretroviral Drug Monitoring Laboratory, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Fedele V; Antiretroviral Drug Monitoring Laboratory, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Bellagamba R; Infectious Diseases Division, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Cicalini S; Infectious Diseases Division, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Ammassari A; Infectious Diseases Division, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Libertone R; Infectious Diseases Division, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Zaccarelli M; Infectious Diseases Division, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Ghisetti V; Division of Infectious Diseases, University of Turin, Turin, Italy.
  • Andreoni M; Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Ceccherini-Silberstein F; Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
  • Bonora S; Division of Infectious Diseases, University of Turin, Turin, Italy.
  • Di Perri G; Division of Infectious Diseases, University of Turin, Turin, Italy.
  • Antinori A; Infectious Diseases Division, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Perno CF; Antiretroviral Drug Monitoring Laboratory, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
  • Santoro MM; Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
J Antimicrob Chemother ; 72(3): 855-865, 2017 03 01.
Article en En | MEDLINE | ID: mdl-27999048
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Fármacos Anti-VIH / Carga Viral / Rilpivirina / Tenofovir / Emtricitabina Tipo de estudio: Prognostic_studies Idioma: En Revista: J Antimicrob Chemother Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Fármacos Anti-VIH / Carga Viral / Rilpivirina / Tenofovir / Emtricitabina Tipo de estudio: Prognostic_studies Idioma: En Revista: J Antimicrob Chemother Año: 2017 Tipo del documento: Article